Clinical trials: Raynaud's Disease
Raynaud's Disease
Dose Response Study of a Topical Formulation of Nitroglycerin for the Treatment of Raynaud's Phenomenon
The purpose of this clinical study is to determine the response to two different dosage strengths of a topical nitroglycerin gel in patients with Raynaud's Phenomenon.
- Trial name
- NCT00480753
- Testing
- Nitroglycerin
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- MediQuest Therapeutics
CREST Syndrome, Peripheral Vascular Disease
Exparel as a Nerve Block for Severe Hand Pain
The purpose of this study is to investigate whether the use of the study drug (Exparel) is safe and effective for treating circulation problems and pain in the hand or fingers.
- Conditions
- CREST Syndrome, Peripheral Vascular Disease, Raynaud Disease, Scleroderma, Diffuse
- Trial name
- NCT02374320
- Testing
- liposomal bupivacaine
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Jose Soberon, MD
Raynaud Phenomenon, Systemic Sclerosis
Cold Challenge With C21 in RP
This is a randomised, double-blind, placebo-controlled, cross-over phase 2 trial investigating the effect of C21 on cold-induced vasoconstriction in subjects with Raynaud's phenomenon secondary to systemic sclerosis.
- Trial name
- NCT04388176
- Testing
- C21
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Vicore Pharma AB
Raynaud Phenomenon
Application for Monitoring and Evaluation of Raynaud's Phenomenon
To evaluate the feasibility of using a smartphone application for monitoring and evaluation of Raynaud's Phenomenon.
- Trial name
- RaynaudMoni (NCT03984422)
- Testing
- Smartphone application
- Where
- France
- Volunteers
- 120 people
- Sponsor
- University Hospital, Grenoble
Raynaud's Phenomenon Secondary to Systemic Sclerosis
Study of Acute Peripheral Vascular Effects, Safety and Tolerability in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis
The purpose of this study is to evaluate pharmacodynamics (PD) in adult subjects with a diagnosis of Raynaud's Phenomenon secondary to Systemic Sclerosis (SSc).
- Trial name
- NCT02228850
- Testing
- Alprostadil
- Where
- 4 sites in United States
- Volunteers
- 35 people
- Sponsor
- NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)
Raynaud Phenomenon
Beet the Cold: The Effect of Inorganic Nitrate Supplementation in Individuals With Raynaud's Phenomenon
Individuals with Raynaud's phenomenon often experience episodes of reduced blood flow to their fingers and toes during times of stress or cold exposure, causing significant discomfort and pain.
- Trial name
- NCT03129178
- Testing
- Concentrated beetroot juice
- Where
- United Kingdom
- Volunteers
- 27 people
- Sponsor
- University of Portsmouth
Post-COVID-19 Condition, Ulcerative Colitis
Emerging Indications for Hyperbaric Oxygen Treatment
This study will evaluate the effectiveness of hyperbaric oxygen therapy (HBOT) on treating emerging indications (i.e., conditions that have shown to potentially benefit from HBOT) using the Multicenter Registry for Hyperbaric…
- Conditions
- Post-COVID-19 Condition, Ulcerative Colitis, Crohn Disease, Calciphylaxis
- Trial name
- NCT07240649
- Testing
- Hyperbaric oxygen treatment (HBOT), 100% Oxygen
- Volunteers
- 100 people
- Sponsor
- Jay C. Buckey Jr.
Systemic Sclerosis, Raynaud's Phenomenon
The Effects of Exercise in Patients With Systemic Sclerosis
Systemic sclerosis (SSc) is a multisystem connective tissue disease characterised by vascular abnormalities and fibrosis, including those of the skin and can be categorised as either Limited cutaneous scleroderma or Diffuse…
- Conditions
- Systemic Sclerosis, Raynaud's Phenomenon, Quality of Life
- Trial name
- NCT03058887
- Testing
- Exercise intervention - Cycling, Exercise intervention - arm cranking
- Where
- 2 sites in United Kingdom
- Volunteers
- 36 people
- Sponsor
- Sheffield Hallam University
Secondary Raynaud's Phenomenon
Safety and Efficacy Study of Gene Therapy Drug (Neovasculgen) to Treat Secondary Raynaud's Phenomenon
The purpose of this study is to determine whether pl-vegf165 (Neovasculgen) is effective in the treatment of digital ulcers related to secondary Raynaud's phenomenon associated with systemic scleroderma
- Trial name
- NCT02356809
- Testing
- Neovasculgen
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- Artgen Biotech
Raynaud Disease, Raynaud's Phenomenon
A Trial of Ischemic Preconditioning in Raynaud's Phenomenon (RP)
This trial will test the efficacy of brief periods of controlled limb ischemia (remote ischemic preconditioning, RIPC) as an effective treatment of patients with Raynaud's Phenomenon (RP).The hypothesis of this trial is that due…
- Trial name
- NCT02506062
- Testing
- Manual blood pressure cuff inflation over brachial artery
- Where
- Canada
- Volunteers
- 21 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Raynaud's Disease, Raynaud Phenomena
Open Label Treprostinil Raynaud's Study
Raynaud's phenomenon is a condition where the blood vessels in participants fingers and toes get too narrow when cold or stressed.
- Conditions
- Raynaud's Disease, Raynaud Phenomena, Raynauds
- Trial name
- NCT07112183
- Testing
- Oral treprostinil (UT-15C) sustained release tablets
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Brigham and Women's Hospital
Raynaud Disease, Raynaud Disease Secondary to Scleroderma
Lab Study of MQX-503 in Treatment of Raynaud's
The purpose of this study is to determine, in comparison to a placebo control, the response to two dosage strengths of a topical gel formulation of nitroglycerin, MQX-303, in the determination of finger blood flow and skin…
- Conditions
- Raynaud Disease, Raynaud Disease Secondary to Scleroderma, Raynaud Secondary to Other Autoimmune Disease
- Trial name
- NCT00253331
- Testing
- topical organogel with nitroglycerin
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- MediQuest Therapeutics
Raynaud's Phenomenon Secondary to Connective Tissue Disease
Efficacy and Safety of Vascana® in Subjects With Secondary Raynaud's Phenomenon
The purpose of this study is to determine the ability of Vascana (0.9% nitroglycerin topical cream) to treat and prevent the symptoms experienced by subject's with Raynaud's Phenomenon.
- Trial name
- NCT02688270
- Testing
- Vascana (0.9% nitroglycerin cream)
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Covis Pharma S.à.r.l.
Raynaud Disease, Hyperemia
PORH and Response to Cold in Raynaud's Phenomenon.
The main objective of the study is to determine if implication of epoxy-eicosatriénoïc acids (EETs) and NO during cutaneous post-occlusive hyperemia differs between patients with Raynaud phenomena and healthy volunteers, by…
- Conditions
- Raynaud Disease, Hyperemia, Cold
- Trial name
- REFRAIN (NCT02183779)
- Testing
- post-occlusive hyperemia, cooling box, L-NMMA and Fluconazole dermic injection
- Where
- France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University Hospital, Grenoble
Raynaud's Phenomenon, Digital Ulcers
A Randomized Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma
Raynaud's phenomenon (RP) associated with scleroderma is a difficult problem to treat. Many patients develop ischemic digital ulcers due to severe RP that causes considerable morbidity and adversely affects the quality of life.
- Conditions
- Raynaud's Phenomenon, Digital Ulcers, Scleroderma
- Trial name
- NCT01117298
- Testing
- Tadalafil
- Where
- 4 sites in India
- Volunteers
- 66 people
- Sponsor
- Sanjay Gandhi Postgraduate Institute of Medical Sciences
Systemic Sclerosis, Raynaud Disease
Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Iloprost for Raynaud's Phenomenon Secondary to Systemic Sclerosis
OBJECTIVES: I. Evaluate the safety and efficacy of oral iloprost, a prostacyclin analog, in patients with Raynaud's phenomenon secondary to systemic sclerosis.
- Trial name
- NCT00004786
- Testing
- iloprost
- Volunteers
- 200 people
- Sponsor
- National Center for Research Resources (NCRR)
Raynaud Phenomenon
The Effect of Abobotulinum Toxin A on the Symptoms of Raynaud's Phenomenon
This study aims to investigate the effect of abobotulinum toxin A on the symptoms of Raynaud's phenomenon.
- Trial name
- NCT03639766
- Testing
- AbobotulinumtoxinA, Saline solution
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- University of Central Florida
Raynaud Phenomenon
Follow-up of SPTS in Patients With Raynaud's Phenomenon
Background: Raynaud's phenomenon is a vasospasm of the extremities, leading to extensive discomfort in daily life and potentially severe ischemia. Some patients are resistant to conventional vasodilatory drug treatment.
- Trial name
- NCT04015193
- Testing
- Single-port thoracoscopic sympathicotomy (patient care)
- Where
- Netherlands
- Volunteers
- 50 people
- Sponsor
- University Medical Center Groningen
Raynaud Phenomenon
Botulinum Toxin in Raynaud's Phenomenon
Raynaud's Phenomenon (RP) is the most common vasospastic disorder encountered by hand surgeons with an estimated prevalence of 5% in the general population. It's manifestations are broad, and can range from minor to severe.
- Trial name
- NCT05125029
- Testing
- Botulinum toxin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Emory University
Raynaud Syndrome
Effects of Vardenafil on Clinical Symptoms and Peripheral Blood Flow in Patients With Raynaud's Syndrome
The purpose of this study is to determine whether vardenafil is effective in improving clinical symptoms and peripheral blood flow in patients with primary and secondary Raynaud phenomenon.
- Trial name
- NCT01291199
- Testing
- vardenafil
- Where
- Germany
- Volunteers
- 57 people
- Sponsor
- University of Cologne